Clinical studies have reported increased serum hepcidin in patients with RA, which was associated with elevated serum IL-6 and tumor necrosis factor alpha (TNF-α), suggesting a potential role of IL-6 inhibition in improving hemoglobin (Hb) levels in patients with RA [13–15]. Here, IL6 is linked to rheumatoid arthritis.